TNFRSF8 and lymphoma: This report contributes to the limited understanding of such dual lymphomas, highlights the role of EBV and cluster of differentiation 30 (CD30) testing in cutaneous lymphoproliferative disorders, and documents a favorable response to rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), and prednisone (R-CHOP) chemotherapy, which may inform future management strategies.